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Background: Ehrlichia chaffeensis is a bacterial pathogen that causes fatal human monocytic ehrlichiosis (HME) that
mimic toxic shock-like syndrome. Murine studies indicate that over activation of cellular immunity followed by
immune suppression plays a central role in mediating tissue injury and organ failure during fatal HME. However,
there are no human studies that examine the correlates of resistance or susceptibility to severe and fatal HME.
Results: In this study, we compared the immune responses in two patients with mild/non fatal and severe/fatal
HME who had marked lymphopenia, thrombocytopenia and elevated liver enzymes. The levels of different
immunological factors in the blood of those patients were examined and compared to healthy controls. Our data
showed that fatal HME is associated with defective production of Th1 cytokines such as ( IFNγ and IL-2), increased
anti-inflammatory (IL-10 and IL-13) and pro-inflammatory (TNF-α, IL-1α, IL-1β, and IL-6) cytokines, increased levels of
macrophages, T cells, and NK cells chemokines such as MCP-1, MIP-1α, MIP-1β, but not RANTES and IP-10, increased
levels of neutrophils chemokine and growth factor (IL-8 and G-CSF), and elevated expression of tumor necrosis
factor receptor (TNFR), and toll like receptors 2 and 4 compared to patients with non fatal HME and healthy
controls.
Conclusions: Fatal Ehrlichia-induced toxic shock is associated with defective Th1 responses, possible immune
suppression mediated by IL-10. In addition, marked leukopenia observed in patients with fatal disease could be
attributed to enhanced apoptosis of leukocytes and/or elevated chemokine production that could promote
migration of immune cells to sites of infection causing tissue injury.
Keywords: Human ehrlichiosis, Toxic shock, T cells, Cytokines, Chemokines, Apoptosis, Ehrlichiosis, Pro-inflammatory
cytokines, Death Receptors, Th1 responseBackground
Human monocytic ehrlichiosis is a prevalent tick borne
bacterial infection of humans caused by the obligately
intracellular bacterium E. chaffeensis, a member of the
family α-protobacteria [1-3]. The disease is associated
with significant mortality (~2.7% mortality rate and 20%
in hospitalized patients) and is characterized by a rapidly
progressive shock-like syndrome preceding death in
patients with fatal illness [4,5]. Histopathologic studies
in patients and murine models of fatal monocytotropic
ehrlichiosis have found widespread extensive necrosis* Correspondence: ismailn@upmc.edu
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reproduction in any medium, provided the orand apoptosis in different organs despite the paucity of
infected cells in human peripheral blood [2,6,7]. In
immunocompromised patients, similar pathology occurs
but in association with an overwhelming infection [8,9].
These pathologic features and the presence of profound
shock in fatal cases of HME have led to the hypothesis
that fatal disease in immunocompetent individuals is
an immune-mediated disease while those in immuno-
compromised patients could be mediated directly by
bacteria inducing tissue damage.
The main target cells for E. chaffeensis are monocytes
and macrophages; however, other cell types such as
endothelial cells and hepatocytes have been observed to
be infected in murine ehrlichial infection [3]. Murine
studies have shown that effective killing of intracellulartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by natural killer T cells and CD4+Th1 lymphocytes
[7,10-17]. However, the number of lymphocytes, mainly
CD4+T cells, declines dramatically in both humans and
animals during fatal disease. Thus, insufficient produc-
tion of IFN-γ by these cells, and thus insufficient activa-
tion of monocytes/macrophages and their intracellular
bactericidal mechanisms, are thought to be the reasons
for severe course of infection [7,10-13]. Furthermore, in
the animal models of fatal ehrlichiosis, development of
tissue injury is associated with expansion of NK cells
and antigen specific CD8+T cells as well as their migra-
tion to peripheral sites of infection such as liver [12,18].
CD8 +T cells and NK cells not only cause severe tissue
injury, but also suppress proliferation of CD4+ Th1 cells
and mediate apoptosis of CD4 + T cells, which could
account for defective Th1 responses and lymphopenia
in fatal ehrlichiosis [12,18].
Although these murine studies reveal immunologic
and pathologic dysfunction that could be attributed to
soluble mediators, there are no published data in
patients with mild/non fatal and severe/fatal disease
regarding the potential pathogenic contribution of these
soluble mediators in HME. In the present report, we
measured the serum levels of cytokines and chemokines
as well as the expression of toll like receptors and apop-
totic receptors that are involved in differential activation
of the immune system and apoptosis of host cells in
patients with non fatal or fatal HME. Our data reveal
that fatal Ehrlichia-induced shock-like syndrome is asso-
ciated with substantial inflammatory responses and weak
protective type-1 immune responses. Furthermore, our
data suggest that TLR4 and TNFR may play a role in the
development of excessive inflammatory responses and
apoptotic cell death in fatal HME. These findings have




A 7 year old patient with acute lymphocytic leukemia
(ALL), who has been in complete remission, was admitted
to the hospital after 4 days of persistent fever for which
he had been treated as an outpatient with ceftriaxone.
Upon admission, his laboratory studies revealed marked
leukopenia (WBC count, 500/μl), anemia (Hgb, 11.5 g/dl),
thrombocytopenia (platelet count, 164,000/μl), neutro-
penia (absolute neutrophil count of 420/μl), and increased
liver enzymes (ALT 636 U/L and AST 1726 U/L). Blood
culture was negative for bacterial and fungal infections.
However, Ehrlichia chaffeensis DNA was detected in the
blood by PCR, but ehrlichiae culture was negative. The
acute serum contained no antibodies to Ehrlichia. There
had been no known tick bite; however, the patient hadrecently returned from camp in a wooded area known to
harbor ticks. He was placed on broad spectrum antibiotics:
cefepime, vancomycin, levofloxacin and doxycycline.
CT scan of the chest demonstrated right lower lobe
pneumonia with moderate right pleural effusion. Cere-
brospinal fluid contained a normal concentration of
protein and glucose. Shortly after admission, he developed
increasing respiratory distress and hypoxia, which necessi-
tated his transfer to the pediatric intensive care unit
(PICU). Later, the patient had increasing respiratory
distress and began having seizure-like activity, developed
significant hyperkalemia, and respiratory and metabolic
acidosis. Despite prolonged resuscitation, the patient’s
condition deteriorated with multiorgan failure syndrome,
and septic shock. He died on day 6 after his admission to
the hospital. The cause of death was attributed to septic
shock secondary to ehrlichiosis. Autopsy examination
showed; 1) cardiomegaly with diffuse focal calcifications in
both ventricles; 2) diffuse alveolar damage; 3) hepatic peri-
portal inflammation and focal fibrosis; and 4) lymphocytic
depletion in the spleen and lymph nodes. The latter was
consistent with presence of leukopenia.
Patient 2
A 24 year old healthy male presented with a 3 day history
of fever, myalgias, and bifrontal headache. Cranial CT was
normal. A history of tick exposure during outdoor activ-
ities was obtained. CSF culture detected no bacteria or
viruses, but contained mild pleocytosis and elevated pro-
tein concentration. All laboratory tests including white
blood cell count, urinanalysis, and chest radiograph were
normal. Serum concentrations of hepatic enzymes were
slightly elevated (ALT 55 U/L and AST 63 U/L). The pa-
tient was treated with broad spectrum antibiotics and an
antiviral drug (vancomycin, ceftriaxone, doxycycline, and
acyclovir). Ehrlichia chaffeensis DNA was detected in the
blood by PCR. The patient was treated with doxycycline
for 10 days and remained afebrile with resolution of his
frontal headache.
Methods
Patients, healthy controls and blood samples
Blood and serum samples were collected from a patient
with fatal HME, a patient with mild HME as well as
gender- and age-matched healthy volunteers. The serum
and blood samples from patient were collected upon
hospital admission and thus represent the acute or early
phase of illness, a time when ongoing inflammatory
responses were likely to be at a maximum. Patient speci-
mens and medical informations that are reported in this
study have been collected with the approval of the office of
research, Institutional Review Board (IRB) at Meharry
Medical College. For patient samples, no consent form is
obtained. This study was considered by the IRB as an
Table 1 Primer used for Reverse Transcriptase (RT-PCR)-
polymerase chain reaction of cytokines, death receptors,
and apoptosis markers in HME patients and controls




TLR2 F: 5'-GGA AGA ATC CTC CAA
TCA GGC-3'
100 NM_003264
R: 5'-CTT CTG TGA GCC CTG
AGG GA-3'
TLR4 F: 5'-AGC CAC GCA TTC ACA
GGG–3',
100 NM_138554
R: 5'-CAT GGC TGG GAT CAG
AGT CC-3'
TLR-9 F: 5’- GTG ACA GAT CCA AGG
TGA AGT-3’
487 NM_017442
R: 5’- CTT CCT CTA CAA ATG
CAT CAC T-3’
Fas F: 5-TGA AGG ACA TGG CTT
AGA AGT G-3’
117 NM_000043
R: 5-GGT GCA AGG GTC ACA
GTG TT-3’
FasL F: 5- GCA GCC CTT CAA TTA
CCC AT-3’
100 NM_000639




F: 5'-TGT GTC TCC TGT AGT
AAA TG-3'
589 NM_001065
R: 5'-ACG AAT TCC TTC CAG
CGC AA-3'
GAPDHF: 5-GAA GGT GAA GGT CGG
AGT C-3’
225 NM_002046
R: 5-GAA GAT GGT GAT GGG
ATT TC-3’
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records and diagnostic specimens that are submitted to
the clinical laboratory at Vanderbilt Medical Center for
diagnostic purposes. Residual samples that remain after
performing the required laboratory diagnostic tests are
considered as discarded samples and thus used in this
study. Patient samples and medical data were collected
and recorded in a manner that subjects cannot be identi-
fied, directly or through any identifiers linked to the
subjects. Blood and sera from healthy controls were col-
lected under the approved IRB protocol and the informed
consent was obtained from healthy individuals.
Total mRNA was extracted from peripheral mono-
nuclear cells, and samples were stored at −80°C until pro-
cessed. Serum and blood samples were collected from
healthy individuals as controls.
Laboratory confirmation of HME
A two-step colorimetric microtiter plate PCR assay capable
of detecting and discriminating medically important
Ehrlichia species was used as described before [19,20].
Isolation of Ehrlichia from patients' blood and strain
identification were performed as described previously
[3-5].
Measurement of cytokines and chemokines in sera
Serum levels of 27 cytokines and chemokines including
IFN–γ, IL-1α, IL–1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10,
IL-12, IL-13, and IL-17, the growth factors, G-CSF, and
GM-CSF, and chemokines, IL-8, MCP-1, MIP-1α, MIP-
1β, and RANTES, were measured in serum samples by
multiplex capture ELISA (Luminex System; Luminex),
according to the manufacturer's directions. Data were
expressed as mean and SD of triplicate measurements of
each cytokine or chemokine in the serum samples. Data
were measured in Pg/ml.
Detection of immune response markers in peripheral
blood leukocytes by quantitative real time PCR
Total RNA was extracted from human blood using
PureLink RNA Mini-extraction Kit (Invitrogen). The
quality of RNA was checked before cDNA preparation.
Reverse transcription of 1μg of RNA was carried out with
the iScript cDNA Synthesis Kit (Invitrogen, Wisc., USA),
following the manufacturer’s protocols. The relative ex-
pression levels of genes of interest were studied by real-
time PCR using My iQ and SYBR green detection system
(Bio-Rad TM, USA). The primer sequences are sum-
marized in Table 1. At the end of each reaction, a melting-
curve analysis was performed to confirm the absence of
primer-dimers. The data were analyzed using the 2 –
ΔΔ Ct method with Ct denoting the threshold cycle of
PCR amplification at which product is first detected byfluorescence. Expression levels of every gene were nor-
malized to the expression level of GAPDH.
Results
Cytokine and chemokine profile in the blood.
In the serum samples obtained at admission or shortly
afterwards, the pro- and anti-inflammatory cytokines
and chemokines that we measured fell into five groups
including: pro-inflammatory cytokines (IL-1α, IL-1β, IL-6,
IL-17, TNF-α), Th1 cytokines (IL-2, IFN-γ, IL-12p70), Th2
cytokines (IL-4, IL-5, IL-9), immunosuppressive or
anti-inflammatory cytokines ( IL-10, IL-13), neutrophil
chemoattractant and growth factors (IL-8, G-CSF), and T
cell, NK cell, and monocyte ckemokines (eotaxin, IP-10,
MCP-1, MIP-1α, MIP-1β, RANTES). Our data show that
fatal HME is associated with substantially increased levels
of pro-inflammatory cytokines such as IL-1α, IL-1β, TNF-
α and IL-6 compared to nonfatal HME, and healthy
controls (Figure 1A). The levels of anti-inflammatory
cytokines such as IL-10 and IL-13 were substantially
increased in fatal disease compared to non-fatal HME
Figure 1 Levels of cytokines and chemokines in the serum samples from healthy controls (4 pooled samples), patient with severe/fatal
or patient with mild/non fatal HME obtained upon hospital admission before antibiotic treatment. Several cytokines and chemokines
described in the Materials and Methods were measured by ELISA and presented in figures A-E. Data were expressed as mean and SD of triplicate
measurements of each cytokine or chemokine in the serum samples. Data were measured in Pg/ml.
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sponse marked by the production of Th1 cytokines; IL-2
and IFN-γ was lower in fatal HME compared to non-
fatal HME (Figure 1C). Weak Th1 response in the pa-
tient with fatal HME was associated with a slight in-
crease in the levels of Th2 cytokines (IL-4 and IL-9)
(Figure 1B) and Th17-cytokine (IL-17) (Figure 1C) when
compared to patient with non-fatal HME and healthy
controls. Interestingly, the levels of IL-8 (Figure 1D) and
G-CSF (Figure 1D), a neutrophil chemoattractant and
neutrophil growth factor, were greatly increased in fatal
HME compared to nonfatal HME and controls, while
the level of GM-CSF was slightly lower in fatal HME
than that detected in nonfatal HME (Figure 1D).Macrophage/monocyte and NK cell chemoattractants
such as MCP-1α, MIP-1α, and MIP-1β were highest in
fatal HME compared to non-fatal HME and healthy
controls (Figure 1E). In contrast, the concentrations of
the T cell chemokine RANTES and IFN-γ dependent
chemokine (IP-10) were lower in fatal HME than in
non-fatal HME, but higher than in healthy controls
(Figure 1E). The strong clustering of high levels of pro-
inflammatory cytokines and monocyte/NK cell chemokines,
but the lower levels of Th1 cytokines, the T cell chemokine
RANTES, and anti-inflammatory cytokines suggests that
fatal disease is associated with excessive pro-inflammatory,
but weak Th1, response at least at the time the patients
are hospitalized.
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HME while a higher expression of TNFR is associated with
fatal disease
One of the main clinical manifestations of HME is marked
leukopenia, mainly affecting the lymphocyte population.
Similarly, in an animal model of fatal ehrlichiosis, death is
accompanied by a substantial decrease in the T cell popu-
lation, mainly CD4+T cells. As expected, these cases of
fatal and nonfatal HME were associated with a decline in
the absolute number of lymphocytes, with severe lympho-
penia in the fatal case (absolute lymphocyte count: fatal
HME=124/μl and nonfatal HME=1720/μl). To examine
whether the difference in lymphocyte levels in these HME
patients was due to apoptosis, we examined the expres-
sion of apoptotic markers on peripheral blood leukocytes.
Our data show that leukocytes from the patient with
milder infection expressed a higher level of FAS mRNA
compared to the patient with fatal ehrlichial infection and
healthy controls. In contrast, leukocytes from the patient
with fatal Ehrlichia infection expressed a higher level of
TNFR mRNA than that expressed in leukocytes from the
patient with milder Ehrlichia infection or healthy controls
(Figure 2A). There was no difference in mRNA expression
of FASL between all groups.Figure 2 Expression levels of TLR2, TLR4, TLR9 and death
receptors (Fas, FasL, and TNFR) on mononuclear cells from
healthy controls and patients with fatal and non fatal HME. The
relative mRNA expression levels of these molecules were normalized
to GAPDH as measured by quantitative real time PCR and described
in the Materials and Methods. Data were expressed as mean and SD
of triplicate measurements of each marker in all patients and healthy
control groups.Increased expression of Toll like receptors-2 and -4 in
fatal human Ehrlichiosis
Recognition of specific microbial ligands by toll like
receptors (TLRs) has been shown to play a major role in
induction of the innate and acquired immune responses
against bacteria, viruses, and protozoa [21,22]. We
examined whether the above quantitative differences in
serum levels of cytokines and chemokines during fatal
and nonfatal HME are due to altered signals through
TLRs. Our data show that leukocytes from the patient
with fatal HME expressed~ 2-fold higher levels of TLR2
and TLR4 compared to leukocytes from the patient with
nonfatal HME or healthy controls (Figure 2B). There
was no difference in expression of TLR9 mRNA between
all groups (Figure 2B).
Discussion
Currently, no human study has examined serum cyto-
kine and chemokine profiles in patients with HME who
present with either moderate or severe disease. Such
studies are critical for enhancing our understanding of
the pathophysiology of Ehrlichia-induced toxic shock.
The development of profound shock, despite the paucity
of infected cells in the blood in patients with severe in-
fection with Ehrlichia, which lack LPS, has been taken
as evidence for subtle immunologic dysfunction attribut-
able to inflammatory mediators. In this study, we com-
pared the levels of circulating pro-inflammatory
cytokines and chemokines derived from or involved in
the activation of immune cells in acute mild-to-moder-
ate/nonfatal or severe/fatal HME with those seen in un-
infected individuals from regions endemic for HME. We
could not determine the statistical significance of the dif-
ferences in the immune responses between the two pa-
tient groups due to small sample size. However, we
believe that this difference is most likely to be biologic-
ally significant based on known levels of these immune
molecules in healthy individuals. Our data here showed
that fatal HME is associated with dysregulated cytokine
and chemokine production with marked elevation of
pro-and anti-inflammatory cytokines, and several che-
mokines that are chemo attractants to NK and T cells.
The presence of uncontrolled elevation of inflammatory
cytokines in patient with fatal HME could contribute to
prolonged activation of Ehrlichia-target cells, which
could possibly contribute to tissue injury and multi-
organ failure.
It is possible that the majority of circulating cytokines
and chemokines are produced within peripheral tissues
that represent main sites of ehrlichial infection such as
liver or lymphoid structures, from where they can leak
into the bloodstream. It should be noted that these
serum cytokine and chemokine expression levels were
studied soon after admission, before progression of the
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HME, respectively. Therefore, the immune profile could
be considered to be predictive of subsequent adverse
events or protection against Ehrlichia. In addition, serum
cytokine and chemokine expression is measured more
easily and is reproducible for rapid clinical diagnostic
purposes.
A salient observation in this study was the high levels
of IL-8 and G-CSF in patient with acute fatal HME. IL-
8, a CXC chemokine, functions as a chemoattractant
for neutrophils and T cells and plays an important role
in the pathogenesis of septic shock associated with
endotoxin [23-26]. G-CSF is shown to be produced as a
compensatory mechanism during bacterial infection that
are associated with bone marrow suppression [23-26].
G-CSF stimulates the survival, proliferation, differenti-
ation and functions of neutrophils precursors and ma-
ture neutrophils [23-26]. However, despite the elevation
of IL-8 and G-CSF, we observed low count of neutro-
phils in the blood of patient with fatal HME. This dis-
cordant result could be due to possible migration of
neutrophils to the peripheral sites of infection or activa-
tion-induced cell death (AICD). In support of the first
possibility, patient with fatal HME had a substantial
elevation of several chemokines, suggesting that an active
migration of inflammatory and immune cells to sites of
infection are taking place. Although it is not yet clear
whether neutrophils play a protective or pathogenic role
during fatal ehrlichial infection in humans, our murine
studies showed a correlation between expansion of neu-
trophils at peripheral sites of infection, ineffective bacterial
elimination, and severe pathology in animal model of fatal
ehrlichiosis, [27] suggesting that neutrophils may play a
pathogenic role in fatal HME.
Activation of monocytes/macrophages killing mechan-
isms by IFN-γ (Th1 cytokine) is the pivotal step in con-
trolling intracellular ehrlichial infection [7,15,28]. Our
data showed that patient with fatal HME had weak Th1
cell-mediated immunity as marked by low serum level of
IL-2 and IFN-γ. However, in the absence of kinetic data
over the course of illness, it is not possible to determine
whether low levels of these Th1 cytokines is due to de-
fective induction of Th1 cells, suppression of T cell prolif-
eration, or AICD. Our murine studies showed that lethal
ehrlichial infection induces apoptosis of CD4+T cells
[7,10-13,18]. However, the exact mechanism by which
CD4+T cells undergo apoptosis in this model is not yet
clear. TNFR and Fas mediated signals are known to be
responsible for apoptosis of host cells during infections
[10]. Patient with fatal HME has higher expression of
TNFR on the mononuclear cells than that detected in the
patient with nonfatal HME, suggesting that signaling via
TNFR, but not Fas/FasL signaling, may be relevant to
observed weak Th1 response. Interestingly, our murinestudies showed that lack of TNFR in lethally infected mice
prolonged their survival and abrogated tissue injury [10].
The high levels of serum IL-10 and IL-13 in the patient
with fatal HME compared to non fatal HME is consistent
with our murine data where IL-10 peaks in the serum
at later stages of lethal infection, which occurs before
animals succumb to infection [7,10,12]. IL-10 is an
immunosuppressive cytokine that inhibits effective
elimination of intracellular bacteria and suppresses T
cell proliferation [29]. Thus, it is possible that IL-10
overproduction in the patient with fatal HME could be
another potential mechanism that account for observed
lymphopenia and week Th1 response.
Finally, our data demonstrated a differential TLRs
expression during fatal and nonfatal HME with upregula-
tion of TLR2 and TLR4 expression in patient with fatal
HME. These data are consistent with TLR expression
during sepsis caused by other lipopolysaccharide (LPS)
positive Gram negative bacterial infection [21,30].
However, unlike other Gram negative bacteria, Ehrlichia
lack LPS, the natural ligand for TLR4. Therefore, upregu-
lation of TLR4 in fatal disease could be induced by other
microbial ligand or by endogenous TLR4 ligand such as
the high-mobility group protein (HMGB1), which is
secreted upon tissue damage [22].
Conclusions
In conclusion, defective production of Th1 cytokines (IL-2
and IFN-γ), but increased pro- and anti-inflammatory
cytokines and marked lymphopenia in patients with severe
and fatal HME is likely to be a key mechanism responsible
for progression of ehrlichial infection to toxic shock and
multi-organ failure in these patients. This study will not
only provide clues for diagnostic markers predictive of
disease progression but also a foundation for further
studies that analyze the effectiveness of immune-based
therapy that target specific inflammatory cytokines or
chemokines. The outcome of effective therapeutic approach
should involve restoration of the Th1-type cytokine produc-
tion as well as decrease immune-mediated tissue injury and
multi-organ failure in patients with severe and fatal
Ehrlichia infection.
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